$AYTU

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi

Original reporting
Published Sep 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AYTU
Neutral
medium confidence
Mentioned
$AYTU
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AYTUNeutralMed
01

Why it matters

The release provides the first public numbers for the EXXUA launch and overall financial health, informing valuation and short‑term trading decisions.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking CNS drug launches and small‑cap earnings beats.

03

What to watch

Cash runway of $26.3 M and upcoming payer negotiations could materially affect future performance.

Relevance 7/10Novelty 8/10Timing: post‑market Sep 22 2026

Background

AYTU BioPharma filed an 8‑K Item 2.02 disclosing its FY2026 and Q4 operational and financial results.

Company-level read

Ticker impact

$AYTUNeutralMedium confidence
Context

SEC 8‑K reports FY2026 and Q4 results with net revenue, adjusted EBITDA and cash balance figures.

Expected impact

Potential modest upside on positive guidance; downside risk if guidance remains weak.

Evidence & confidence

Results are primary disclosure but small scale; market may price in incremental improvement.

Market effects

Highlights growth trajectory for CNS specialty pharma and EXXUA launch within the MDD market.

US‑focused; limited broader regional effect.

Minimal global impact beyond niche CNS sector.

Counterpoint

Revenue decline year‑over‑year and negative adjusted EBITDA suggest the stock may face pressure despite launch momentum.

Key entities

  • Josh Disbrow

    Chief Executive Officer of AYTU providing commentary on results.

Related articles

$NFLXHighAI 8/10

Netflix Q3 2026 Earnings Report: Revenue Meets Estimates Amid Restructuring

Netflix reported Q3 2026 revenue of $12.87B, up 11.8% YoY, meeting estimates but showing slowed growth. The company is restructuring, laying off 1,000 employees and appointing new leadership. Q4 revenue is projected at $13.4B, below expectations, with adjusted ad revenue forecast at $2.7B. Engagement metrics show a decline in average viewing time per member.

$GNTXMedAI 8/10

Gentex Corp (GNTX) (Q3 2026) Earnings Call Highlights: Navigating Revenue Misses

Gentex Corp (GNTX) reported Q3 2026 revenue of $647.7M, missing forecasts by $35M. Non-automotive revenue grew 17%, while automotive revenue declined 3%. Gross margin fell to 33.4% due to cost pressures. The company maintained its 2027 revenue outlook of $2.8B-$2.9B, citing growth opportunities and one-time issues. It repurchased 5.7M shares in Q3 and secured an $180M PCBA award. Challenges include supply chain constraints and higher component costs.

$WDCMedAI 8/10

Western Digital Stock Falls 3% After Beat: Sandisk Oct 29

Western Digital (WDC) stock fell 3% to $343.67 on Friday, despite beating earnings estimates and providing strong guidance. The company reported fiscal Q1 2027 non-GAAP earnings of $4.64 per share, revenue of $4.38 billion, and forecasted Q2 revenue of $5.1 billion with earnings of $5.80 per share. The decline may reflect investor concerns about storage pricing and AI infrastructure financing. Sandisk (SNDK), which reports earnings on October 29, may be impacted by these trends.